Background
Isosporiasis is an uncommon diarrheal illness caused by the protozoan Isospora belli. Isospora was first described by Virchow in 1860. The genus Isospora is related closely to the genera Cryptosporidium, Cyclospora, and Toxoplasma. The first case of human infection with I belli was described In 1915.[1]
Humans are the only known hosts for I belli, which has no known animal reservoir. Isosporiasis has a worldwide distribution, although it is more common in tropical and subtropical climates. (See Epidemiology.)
I belli infection usually causes a mild and protracted illness unless the patient is immunocompromised. (See Clinical.) Clinical presentation may mimic those of inflammatory bowel disease and irritable bowel syndrome.
The diagnosis of isosporiasis is based on a combination of clinical, epidemiological, and diagnostic tests. (See Workup.) Isosporiasis is an AIDS-defining illness, so an appropriate workup for HIV infection should be performed, if necessary.
Although isosporiasis is generally a self-limited infection, patients who are treated tend to improve in 2-3 days, whereas those who are not remain sick considerably longer. (See Treatment.) Immunocompetent hosts generally respond very rapidly to antiparasitic therapy. Immunocompromised hosts also respond well, though less rapidly; however, they have a high relapse rate once therapy is stopped and thus typically require indefinite prophylaxis after therapy.
Pathophysiology
I belli is ingested in contaminated food or water, and its life cycle requires a stage outside the host. After mature I belli oocysts are ingested, they liberate sporozoites (possibly in response to bile in the small intestine), which invade the enterocytes of the proximal small intestine. Here, they become trophozoites, and asexual multiplication (schizogony) produces merozoites that invade previously uninfected cells.
Shortly thereafter, a sexual multiplication cycle (sporogony) begins, generating oocysts that may pass into the environment. Outside the host, oocysts mature and become infectious 2-3 days later. The oocysts of I belli are resistant and remain viable in the environment for months.
Symptoms of isosporiasis suggest a toxin-mediated mechanism, but no toxin has been identified. In humans, extraintestinal forms of isosporiasis are rare; however, they have been reported in patients with AIDS.
Etiology
The causative pathogen of isosporiasis is I belli, a protozoan that belongs to the subclass Coccidia in the phylum Apicomplexa. The mode of transmission of isosporiasis is fecal-oral, ie, through food or water contaminated with human feces. In immunocompetent hosts, I belli infection causes a self-limited diarrheal illness. In individuals with immunocompromise, it may cause chronic life-threatening diarrhea and dehydration.
Exposure to contaminated food or water predisposes to this infection. Because an external stage in the environment is required for the oocysts to mature, direct person-to-person transmission is unlikely. Accordingly, isosporiasis is more common in areas with poor sanitation. The disease is also more common in patients with AIDS.
Epidemiology
United States statistics
The exact incidence of isosporiasis in humans is unknown. I belli has been reported as the cause of outbreaks of diarrheal illness in daycare centers and mental institutions and has been implicated in traveler’s diarrhea in endemic areas.[2]
I belli infection is distinctly rare among immunocompetent individuals. Isosporiasis is more common in persons with AIDS, 0.2-3% of whom have stools positive for Isospora; however, this increased prevalence has been reduced by the widespread use of Pneumocystis jiroveci pneumonia (PCP) prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMZ) among patients with HIV infection.
In Los Angeles from 1985 to 1992, 1% of patients with AIDS had stools positive for Isospora.[6] Infection was more common in foreign-born and Hispanic residents with AIDS (eg, those from El Salvador [7.4%] or Mexico [5.4%]) and less common in those receiving TMP-SMZ prophylaxis for Pneumocystis infection.[6]
Isosporiasis has also been reported in patients with lymphoma and leukemia and recipients of renal and liver transplants.
International statistics
Endemic areas of isosporiasis include Africa,[7] Australia, the Caribbean Islands, Latin America, and Southeast Asia. One study found positive examination findings in up to 15% of Haitians infected with AIDS.[8] In developing countries, 8-40% of patients with AIDS are infected.
Isosporiasis is the initial AIDS-defining illness in approximately 2-3% of patients with AIDS who are from Africa. Among patients with AIDS who are from South America, 10% with chronic diarrhea have isosporiasis. In patients with AIDS who are from Haiti and Africa, 7-20% with chronic diarrhea have isosporiasis.
Age-, sex- and race-related demographics
People of all ages are susceptible to I belli infection, although it tends to be more serious in infants and young children, possibly as a result of the risk of dehydration in this population. I belli can cause severe diarrhea in infants.
No gender predilection for infection has been noted, aside from the gender distribution of people with AIDS, the risk factor most commonly associated with this disease.
No racial predilection for isosporiasis has been reported, other than the racial distribution of people with AIDS. Among people with AIDS in the United States, Hispanics appear to be more at risk than blacks or whites, likely secondary to importation.
Prognosis
Prognosis is excellent with therapy (and prophylaxis, if appropriate).
In immunocompetent patients, isosporiasis is usually a transient, self-limited illness but can sometimes result in a protracted diarrheal illness. Isosporiasis has also been reported as a contributor to malabsorption syndrome in immunocompetent patients.[3]
In patients with AIDS, isosporiasis can range in severity from a chronic and intermittent illness to a severe and life-threatening diarrheal illness.
Woodcock HM. Notes on Protozoan parasites in the excreta. BMJ. 1915;2:709..
Goodgame R. Emerging Causes of Traveler's Diarrhea: Cryptosporidium, Cyclospora, Isospora, and Microsporidia. Curr Infect Dis Rep. Feb 2003;5(1):66-73. [Medline].
Sasaki M, Tanaka A, Nishimura T, Tsujikawa T, Andoh A, Ishizuka I, et al. A case of malabsorption syndrome caused by isosporiasis in an immunocompetent patient. J Gastroenterol. Jan 2004;39(1):88-9. [Medline].
ten Hove RJ, van Lieshout L, Brienen EA, Perez MA, Verweij JJ. Real-time polymerase chain reaction for detection of Isospora belli in stool samples. Diagn Microbiol Infect Dis. Jul 2008;61(3):280-3. [Medline].
Malik S, Samantaray JC, Bagga A, Das A. Refractory isosporiasis. Indian J Pediatr. May 2005;72(5):437-9. [Medline].
Sorvillo FJ, Lieb LE, Seidel J, Kerndt P, Turner J, Ash LR. Epidemiology of isosporiasis among persons with acquired immunodeficiency syndrome in Los Angeles County. Am J Trop Med Hyg. Dec 1995;53(6):656-9. [Medline].
Rowe JS, Shah SS, Motlhagodi S, Bafana M, Tawanana E, Truong HT, et al. An epidemiologic review of enteropathogens in Gaborone, Botswana: shifting patterns of resistance in an HIV endemic region. PLoS One. Jun 2 2010;5(6):e10924. [Medline]. [Full Text].
DeHovitz JA, Pape JW, Boncy M, Johnson WD Jr. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med. Jul 10 1986;315(2):87-90. [Medline].
Limson-Pobre RN, Merrick S, Gruen D, Soave R. Use of diclazuril for the treatment of isosporiasis in patients with AIDS. Clin Infect Dis. Jan 1995;20(1):201-2. [Medline].
Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis. Apr 15 2005;40(8):1173-80. [Medline].
Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. Mar 2002;18(3):95-7. [Medline].

